DNA Testing Market Is Expected To Propel Growth Based On Account Of Increasing Adoption Of Precision Medicine Diagnostic Techniques Till 2022: Grand View Research, Inc.


(MENAFNEditorial) According to report published by Grand View Research, Global DNA testing market size was valued at USD 6,206.3 million in 2014. Introduction of novel technologies for genome profiling are expected to boost progress of this industry over the forecast period. Globalis anticipated to reach USD 10.04 billion by 2022, according to a new study by Grand View Research Inc. Rise in developments in the field of genome sequencing and personalized DNA level diagnostic applications, a considerable growth in the number of patented research initiatives by the government and government funded projects are factors expected to drive demand during the forecast period.

Introduction of novel technologies for genome profiling are expected to boost progress of this industry over the forecast period. Furthermore, increasing incidences of chronic oncology and infectious diseases that depend on DNA prototyping for treatment and diagnosis using personalized medicine are anticipated to significantly raise demand for DNA diagnostics/testing based research thereby propelling industrial growth in the coming years. Increasing demand for prenatal testing andin-vitrofertilization that subsequently leads to rise in demand for DNA diagnostics/testing is also attributive towards expected progress in this market.

Full Research Report on Global DNA Testing Market Analysis:

U.S. DNA testing market, by application, 2012 - 2022 (USD Million)

Further key findings from the study suggest:

PCR based diagnosis accounted for the largest share of the market revenue in 2014 as a result of higher preference rate coupled with higher availability of products and reagent kits of this segment. Next generation sequencing application for DNA testing is estimated to witness significant progress with a double digit CAGR of over 16% amongst the other technology segments due to presence of significant advantages offered by this technique of DNA identification and testing. Infectious disease diagnostics accounted for the largest market share in 2014 due to higher incidence rate of various infectious disorders which subsequently raises the demand forin-vitronucleic acid based diagnostic tests for diagnosis and monitoring of disease progression. There are diverse applications of DNA testing market out of which oncology diagnostics and histopathology is estimated to register lucrative growth over the forecast period. Factors attributing for considerable growth potential in this segment include identification of cancer causing genes & associated research, and facilitation in mutation detection North America dominated the market in 2014, with revenue estimated at over USD 2,600 million. Presence of sophisticated healthcare infrastructure, rising incidence of genetic abnormalities, favorable government initiatives with respect to genetic diagnosis and its application inin-vitrofertilization are major factors driving growth of this region. Asia Pacific is anticipated to witness lucrative growth as a result of developments in health care infrastructure in this region coupled with presence of significant number of target population that is suffering with chronic as well as acute disorders. Government initiatives taken up herein are also attributive to influence sector growth to a great extent. Key participants of DNA testing industry include Abbott Laboratories, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Applied Biosystems Group, Cepheid Inc., Transgenomic Inc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Alere Inc, Affymetrix Inc., Hologic, Dako, and 454 Life Sciences.
View more reports of this category by Grand View Research at:

Grand View Research has segmented DNA Testing Market on the basis of technology, application, and region:

GlobalDNA Diagnostics/Testing Technology Outlook (Revenue, USD Million, 2012 - 2022)

Microarrays based diagnostics PCR based diagnostics In-situ hybridization diagnostics NGS DNA diagnosis Global DNA Diagnostics/Testing Application Outlook (Revenue, USD Million, 2012 - 2022)

Prenatal DNA Carrier Screening Preimplantation Diagnosis Newborn Genetic Screening Infectious Disease Diagnostics HBV Diagnostic HCV Diagnostic HIV Diagnostic TB Diagnostic CT/NG Diagnostic HPV Diagnostic MRSA Diagnostic Others Oncology Diagnostics & Histopathology Identity Diagnostics & Forensics Pharmacogenomics Diagnostic Testing Drug Metabolism & P450 effects Others DNA Diagnostics/Testing Regional Outlook (Revenue, USD Million, 2012 - 2022)

North America U.S. Canada Europe Germany UK Asia Pacific Japan China Latin America Brazil Mexico MEA South Africa
View Press Release Of This Research Report By Grand View Research:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. Thecompany provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and healthcare.

For more Information visit:

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.
Email:
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website:

MENAFN2407201700703268ID1095653528


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.